Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Labenz

Showing results (151-160 of 172) with videos related to

Pageof 18
Sort By:
Digestive Diseases (Basel, Switzerland)|September 24, 2004
What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa?M Vieth, U Peitz, J Labenz, et al.
Alimentary Pharmacology & Therapeutics|January 6, 2006
Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagusM Vieth, M Kulig, A Leodolter, et al.
Alimentary Pharmacology & Therapeutics|June 19, 2008
Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastro-oesophageal reflux disease: a matched case-control studyK Monkemuller, H Neumann, M Nocon, et al.
Journal of Clinical Epidemiology|July 13, 2004
Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD studyM Kulig, M Nocon, M Vieth, et al.
Alimentary Pharmacology & Therapeutics|November 11, 2011
Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD studyP Malfertheiner, M Nocon, M Vieth, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2003
Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD StudyD Jaspersen, M Kulig, J Labenz, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2003
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiativeM Kulig, A Leodolter, M Vieth, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 18, 2006
Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD studyD Jaspersen, J Labenz, S N Willich, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2005
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO studyJ Labenz, D Armstrong, K Lauritsen, et al.
Alimentary Pharmacology & Therapeutics|October 18, 2005
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO studyJ Labenz, D Armstrong, K Lauritsen, et al.
Pageof 18

Showing results (151-160 of 172) with videos related to

Sort By:
Pageof 18
Digestive Diseases (Basel, Switzerland)|September 24, 2004
What parameters are relevant for the histological diagnosis of gastroesophageal reflux disease without Barrett's mucosa?M Vieth, U Peitz, J Labenz, et al.
Alimentary Pharmacology & Therapeutics|January 6, 2006
Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagusM Vieth, M Kulig, A Leodolter, et al.
Alimentary Pharmacology & Therapeutics|June 19, 2008
Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastro-oesophageal reflux disease: a matched case-control studyK Monkemuller, H Neumann, M Nocon, et al.
Journal of Clinical Epidemiology|July 13, 2004
Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD studyM Kulig, M Nocon, M Vieth, et al.
Alimentary Pharmacology & Therapeutics|November 11, 2011
Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD studyP Malfertheiner, M Nocon, M Vieth, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2003
Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD StudyD Jaspersen, M Kulig, J Labenz, et al.
Alimentary Pharmacology & Therapeutics|October 11, 2003
Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease-- an analysis based on the ProGERD initiativeM Kulig, A Leodolter, M Vieth, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 18, 2006
Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD studyD Jaspersen, J Labenz, S N Willich, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2005
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO studyJ Labenz, D Armstrong, K Lauritsen, et al.
Alimentary Pharmacology & Therapeutics|October 18, 2005
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO studyJ Labenz, D Armstrong, K Lauritsen, et al.
Pageof 18